COVID-19 Clinical Trial
Official title:
An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19
Rationale: Currently there are no approved treatments for COVID-19. In the Dutch treatment
protocol guideline (SWAB) designated treatment is supportive care with the option to add
chloroquine base (CQ) or hydroxychloroquine (HCQ). CQ and HCQ are implemented because of
their in vitro activity, results from small animal studies, and anecdotal patient's data.
There are no published randomized studies with these medications in patients with disease
caused by any coronavirus.
Objective: To evaluate if treatment with only supportive care or addition of one of two
anti-COVID_19 agents (chloroquine or hydroxychloroquine) results in less disease progression
in patients with moderate to severe COVID-19 who require hospital admission.
Study design: Multicentre, cluster randomized cross-over, open label trial. Hospitals will be
randomly allocated to one of 3 treatment arms in sequential periods of one week: chloroquine
base versus hydroxychloroquine versus supportive care without any drug presumed active
against SARS-COV-2. Patients will be treated based on the date of inclusion.
Study population: Adults aged of 18 years and older with moderate to severe, with a NEWS-2
score ≤ 5, laboratory confirmed COVID-19, who require hospital admission in a ward outside
the Medium Care or Intensive Care.
Intervention (if applicable): Depending on the treatment arm, the study subject will receive
only supportive care or an addition with one of the two agents active against SARS-CoV-2
(chloroquine or hydroxychloroquine).
Main study parameters/endpoints: Disease progression defined as a NEWS-2 score ≥ 7 within 14
days, or admission to Medium Care or Intensive Care Unit, or death.
Study rationale CQ and HCQ were both employed in the treatment of COVID-19 in China. Based on
unpublished anecdotal positive results in China, CQ is now implemented in China and the
Netherlands in severe COVID-19. HCQ is an analog of CQ with more anti-viral effectivity ex
vivo, better safety and tolerability profile.
Rationale for the employment of CQ and HCQ in China comes from the fact that both reduce
COVID-19 replication ex-vivo. On top of this, both drugs have clear immunomodulating effects
(which is used for various indications to treat rheumatologic diseases) and have shown
promising results in patients with dengue and HIV.
Currently, in the Dutch guidelines, for moderate severely ill patients CQ base is the first
line of therapy for patients admitted in hospital with moderate to severe COVID-19.
The time needed to "load" the body when using CQ and thus the possible late onset of action
suggests that initiation of treatment should be timely. Moreover, the hypothesized mode of
action suggests that both HCQ and CQ inhibit cellular replication of COVID-19 but do not have
an intrinsic effect on the virus, thus could be best employed when the viral load is low
(i.e. early phase of the disease) and thus safe time to improve the subsequent immune
response. This underlines that both drugs should be implemented early rather than late in the
course of SARS-COV-2 infection.
The investigators propose a cluster randomized controlled study evaluating the value of
chloroquine and hydroxychloroquine compared to no antiviral therapy in admitted patients with
moderate to severe COVID-19.
Study design:
Population Adult patients with confirmed COVID-19, with moderate to severe symptoms and
admitted to the hospital and a NEWS-2 score ≤ 5, will be available for the study.
Intervention
All three treatment arms contain standard supportive care during hospital admission with in
two arms an addition with either chloroquine (CQ) or hydroxychloroquine (HCQ) Despite the
inclusion of CQ and HCQ as possible additional treatment for COVID-19 in the Dutch treatment
guideline, there's no conclusion on the best treatment strategy in this population. Based on
pharmacokinetic modelling, and the safety profile, HCQ seems to be more promising than CQ,
but both drugs have to be studied in relation to COVID-19. Furthermore, the availability of
both drugs might differ from country to country; in the Netherlands for instance, chloroquine
is widely available. Therefore, a 1:1:1 trial including standard supportive care with in
addition CQ or HCQ as suggested in the LCI/SWAB guideline, the optimal dosages in the
different treatment arms are as follows:
1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours
later, followed by 300mg bid for 4 days; total treatment duration of 5 days
2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid
for 4 days; total treatment duration of 5 days.
3. Supportive care only. Dosage of chloroquine and Hydroxychloroquine will be adjusted, if
the patients has a renal impairment with an estimated glomerular filtration rate (eGDR)
<10, to 50% of the initial dosage.
If patient will be discharged from hospital before the end of the treatment, treatment is
continued outside of the hospital. The general practitioner will receive note of the
treatment at discharge.
Main studyendpoint Composite endpoint with disease progression defined as a NEWS2score ≥ 7
within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death
within 14 days.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|